Source disclosure: January 23, 2026
JCR Pharmaceuticals Co., Ltd. [4552.T]
TOKYO, Jan 23 (Pulse News Wire) – JCR Pharmaceuticals CO.,LTD. (4552.T) entered into an exclusive licensing agreement with Italfarmaco for the development and commercialization of Givinostat, a treatment for Duchenne Muscular Dystrophy (DMD).
The deal grants JCR Pharmaceuticals an exclusive license for Givinostat's distribution in Japan. Both companies aim to expand their portfolios through strategic collaboration and explore joint opportunities within JCR’s research and development pipeline and foundational technologies. Under the agreement, Givinostat, which is currently approved in the United States and Europe but not yet in Japan, targets patients aged six and older who are ambulatory and those with specific genetic mutations.
The drug offers a non-steroidal approach to treating DMD, addressing multiple disease-modifying pathways irrespective of genetic variations. Clinical trials indicate reduced inflammation, enhanced muscle repair, and improved motor function among treated patients. This partnership underscores JCR Pharmaceuticals' commitment to advancing treatments for rare diseases, particularly focusing on innovative therapies beyond traditional steroid-based options.
The company plans to leverage its expertise alongside Italfarmaco to accelerate Givinostat's regulatory approval process in Japan and enhance patient accessibility to this promising therapy.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing